U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07320326) titled 'ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab' on Dec. 09, 2025.
Brief Summary: This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
Study Start Date: Dec. 30, 2025
Study Type: OBSERVATIONAL
Condition:
TCE-RRMM
Intervention:
DRUG: Elranatamab
In the retrospective period, Each patient will be followed up until two years after the first dose of Elranatamab treatment, death, or withdrawal of consent, whichever occur...